Literature DB >> 23926726

Long-term survival of proximal humerus allografts for reconstruction following resection of malignant bone tumours.

Gareth Squire1, Tom J Grundy, Nicholas A Ferran, William M Harper, Robert U Ashford.   

Abstract

We previously reported early favourable results concerning allograft use in proximal humerus reconstruction following malignancy. We now present the long-term follow-up of patients who underwent tumour resection with massive humeral allograft reconstruction. This is a retrospective review of 8 consecutive patients who underwent massive proximal humeral allograft for primary or secondary bone tumours. The median age at first surgery was 41 years; the median followup is 11.1 years. The overall revision rate of the allografts was 75%. A total of 10 revision procedures were required in this cohort. Five-year survival for implants was 44%; at ten years no implants were intact. Five-year survival for patients was 88%; it was 60% at ten years. In our experience, proximal humerus allograft reconstruction was associated with a high complication rate and resulted in multiple revision procedures in the long-term. We no longer perform or recommend this procedure.

Entities:  

Mesh:

Year:  2013        PMID: 23926726

Source DB:  PubMed          Journal:  Acta Orthop Belg        ISSN: 0001-6462            Impact factor:   0.500


  3 in total

1.  Endoprosthetic reconstruction of the proximal humerus after tumour resection with polypropylene mesh.

Authors:  Baichuan Wang; Qiang Wu; Jianxiang Liu; Shuhua Yang; Zengwu Shao
Journal:  Int Orthop       Date:  2014-11-23       Impact factor: 3.075

2.  Limb salvage: When, where, and how?

Authors:  Ajay Puri
Journal:  Indian J Orthop       Date:  2015 Jan-Feb       Impact factor: 1.251

3.  Proximal Humerus Tumors: Higher-than-Expected Risk of Revision With Constrained Reverse Shoulder Arthroplasty.

Authors:  Mehmet Ayvaz; Riza Mert Cetik; Sancar Bakircioglu; A Mazhar Tokgozoglu
Journal:  Clin Orthop Relat Res       Date:  2020-11       Impact factor: 4.755

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.